WORK Medical Technology Group LTD (WOK) AI Stock Analysis

• Market Cap: $3.11M
• Dividend Yield: N/A
• Average Volume (3M): 33.96M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.55
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 216
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): N/A
• Shares Outstanding: 79,054,535
• 10 Day Avg. Volume: 36,631,792
• 30 Day Avg. Volume: 33,957,643
• PEG Ratio: <0.01
• Price to Book (P/B): 5.03
• Price to Sales (P/S): 5.77
• P/FCF Ratio: -5.78
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 41 Neutral
• Price Target: $3.50 ▼(-2.51% Downside)

The overall stock score is heavily influenced by the company's poor financial performance and negative technical indicators. The lack of earnings call data and corporate events further limits positive factors. The stock's low valuation score reflects uncertainty due to missing P/E and dividend yield data.

WORK Medical Technology Group LTD Business Overview & Revenue Model

Company Description

WORK Medical Technology Group LTD (WOK) is a pioneering company in the healthcare technology sector, specializing in the development and commercialization of innovative medical devices and digital health solutions. The company focuses on improving patient outcomes through advanced technology, offering a range of products including diagnostic tools, wearable health monitors, and telehealth platforms. WOK is committed to enhancing the efficiency and effectiveness of healthcare delivery, catering to both clinical environments and patients at home.

How the Company Makes Money

WORK Medical Technology Group LTD generates revenue through multiple streams, primarily from the sale of its medical devices and digital health solutions. The company sells its products to hospitals, clinics, and healthcare providers, which constitutes a significant portion of its income. Additionally, WOK earns revenue through subscription services associated with its telehealth platforms, allowing healthcare providers to offer remote care solutions. Partnerships with healthcare institutions and technology companies also play a crucial role in expanding its market reach and driving sales. Furthermore, WOK may engage in research collaborations and grants that contribute to its funding and innovation efforts, enhancing its overall earnings potential.

WORK Medical Technology Group LTD Financial Statement Overview

Summary

WORK Medical Technology Group LTD faces significant financial challenges, with declining revenues, operational inefficiencies, and high leverage. The company's inability to generate positive cash flow from operations and reliance on external financing pose risks to its financial health. Strategic improvements are necessary to enhance profitability and stabilize cash flows.

Income Statement

The company has experienced a significant decline in revenue over the past few years, with a negative revenue growth rate from 2020 to 2024. Gross profit margin has decreased, and the company is currently operating at a net loss, indicating challenges in maintaining profitability. The negative EBIT and EBITDA margins further highlight operational inefficiencies.

Balance Sheet

The balance sheet shows a high level of debt relative to equity, with a debt-to-equity ratio indicating potential leverage risks. The equity ratio is moderate, suggesting a balanced asset structure. However, the negative return on equity reflects poor profitability, impacting overall financial stability.

Cash Flow

The cash flow statement reveals negative free cash flow growth, indicating difficulties in generating cash from operations. The operating cash flow to net income ratio is negative, suggesting inefficiencies in converting income into cash. The company relies heavily on financing activities to sustain operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	10.74M	11.51M	13.57M	19.71M	45.86M	52.53M
Gross Profit	2.89M	2.87M	4.14M	4.42M	8.64M	10.85M
EBITDA	-4.09M	-1.71M	2.08M	4.72M	11.87M	4.75M
Net Income	-3.71M	-3.49M	112.03K	865.21K	5.96M	1.16M
Balance Sheet
Total Assets	34.71M	36.25M	29.96M	25.54M	30.66M	56.20M
Cash, Cash Equivalents and Short-Term Investments	2.00M	6.56M	1.60M	731.18K	508.71K	200.40K
Total Debt	13.04M	13.47M	9.10M	6.30M	6.60M	4.05M
Total Liabilities	19.00M	20.18M	18.97M	14.35M	19.26M	50.27M
Stockholders Equity	12.95M	13.19M	9.88M	10.00M	10.04M	4.90M
Cash Flow
Free Cash Flow	-13.20M	-11.49M	1.63M	-4.27M	-7.24M	9.65M
Operating Cash Flow	-3.76M	-2.23M	2.21M	-2.26M	-7.18M	27.20M
Investing Cash Flow	318.29K	-9.06M	-583.30K	-1.35M	-60.00K	-16.84M
Financing Cash Flow	2.05M	15.66M	-728.72K	3.57M	7.99M	-10.28M

WORK Medical Technology Group LTD Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 3.59
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Positive
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For WOK, the sentiment is Negative. The current price of 3.59 is below the 20-day moving average (MA) of 5.43, below the 50-day MA of 38.74, and below the 200-day MA of 86.76, indicating a bearish trend. The MACD of -8.87 indicates Negative momentum. The RSI at 19.45 is Positive, neither overbought nor oversold. The STOCH value of 37.08 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for WOK.

WORK Medical Technology Group LTD Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MHUA	―	$7.10M	0.72	5.90%	―	-4.99%	-19.11%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
FEMY	―	$26.73M	―	-329.45%	―	98.61%	-1.98%
WOK	―	$3.11M	―	―	―	―	―
MLSS	―	$32.96M	-4.83	-123.50%	―	7.84%	-43.00%

WORK Medical Technology Group LTD Corporate Events

WORK Medical Technology Group LTD Implements Share Consolidation to Meet Nasdaq Requirements

On September 12, 2025, WORK Medical Technology Group LTD held an extraordinary general meeting where shareholders approved resolutions for a share consolidation and an increase in authorized share capital to ensure compliance with Nasdaq’s minimum bid price requirement. The consolidation, effective October 21, 2025, adjusted the company’s share structure to prevent delisting risks, with shares now trading under the same symbol ‘WOK’ but with a new CUSIP number. This strategic move aims to stabilize the company’s market position and maintain its Nasdaq listing, impacting shareholders by consolidating shares at a 100:1 ratio and increasing authorized capital to $10 million.

WORK Medical Technology Group Announces Extraordinary General Meeting for Share Capital Changes

WORK Medical Technology Group LTD has announced an extraordinary general meeting scheduled for November 7, 2025, to discuss significant changes to its share capital structure. The meeting will address resolutions to increase the company’s authorized share capital from $10 million to $100 million and to consolidate shares, which could impact shareholder value and market positioning. These changes follow a previous board decision on September 29, 2025, to consolidate and increase share capital, reflecting the company’s strategic efforts to enhance its financial flexibility and operational capacity.

WORK Medical Technology Group Secures $2.9 Million in Registered Direct Offering

On September 25, 2025, WORK Medical Technology Group LTD announced a securities purchase agreement with institutional investors, resulting in a registered direct offering of 22,055,096 Class A ordinary shares and pre-funded warrants for 16,944,238 shares, raising approximately $2.9 million. The offering, which closed on September 26, 2025, aims to bolster the company’s working capital and general corporate purposes. This move is expected to enhance the company’s financial flexibility and market positioning, with implications for stakeholders including a lock-up agreement for directors and major shareholders, and restrictions on further share issuance for a specified period.

WORK Medical Technology Group Approves Key Resolutions at September 2025 Meeting

On September 12, 2025, WORK Medical Technology Group LTD held an Extraordinary General Meeting of Shareholders, where several key resolutions were approved. These included a potential share consolidation, a share capital increase, and amendments to the company’s memorandum of association. The decisions aim to enhance the company’s financial structure and operational flexibility, potentially impacting its market positioning and shareholder value.

WORK Medical Technology Group LTD Releases Financial Results for H1 2025

WORK Medical Technology Group LTD has released its unaudited financial statements for the six months ended March 31, 2025. The report highlights a decrease in net revenue compared to the previous year, with $4.5 million in revenue from third parties and $37,892 from related parties. The company experienced a gross profit of $1.56 million, but faced increased operating expenses, resulting in a challenging financial period. This financial disclosure may impact the company’s market perception and stakeholder confidence.

WORK Medical Technology Group Announces Extraordinary Shareholder Meeting for Strategic Resolutions

WORK Medical Technology Group LTD has announced an extraordinary general meeting of shareholders scheduled for September 12, 2025. The meeting will address several resolutions, including potential share consolidations and an increase in authorized share capital. These measures aim to enhance the company’s financial structure and flexibility, potentially impacting its market positioning and shareholder value.

WORK Medical Technology Group LTD Changes Independent Auditor

On July 29, 2025, WORK Medical Technology Group LTD’s board approved the change of its independent auditor from WWC, P.C. to HTL International, LLC, effective July 30, 2025. This decision follows a period without disagreements or reportable events with the previous auditor, WWC, indicating a smooth transition in the company’s auditing processes.